HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Drop in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 23,758 shares, a decline of 56.0% from the January 29th total of 53,964 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average daily volume of 115,610 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 115,610 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $35.00.

HCW Biologics Stock Performance

HCW Biologics stock traded down $0.01 during trading on Friday, reaching $0.54. The company had a trading volume of 28,799 shares, compared to its average volume of 144,630. The firm’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $2.67. HCW Biologics has a 1-year low of $0.50 and a 1-year high of $17.80. The firm has a market capitalization of $1.77 million, a PE ratio of -0.04 and a beta of 0.72.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC acquired a new position in HCW Biologics Inc. (NASDAQ:HCWB) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned about 0.69% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is owned by institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.